Retatrutide (GLP-1/GIP/Glucagon triple agonist)
Clinical evidenceRetatrutide is a GLP-1/GIP/glucagon triple agonist with strong human clinical data for weight loss and metabolic improvement. It represents a latest-generation breakthrough in incretin therapy. Not medical advice; consult a provider.
How Retatrutide (GLP-1/GIP/Glucagon triple agonist) works
Retatrutide has shown strong human clinical results and is considered a latest breakthrough in the incretin space. Use only under a healthcare provider; not for self-directed use.
Researched benefits
- •Substantial weight loss in human trials
- •Improved metabolic markers
- •Triple agonist mechanism (GLP-1, GIP, glucagon)
- •Emerging human clinical results
What it is studied for
- •Weight loss and body composition
- •Metabolic health and insulin sensitivity
- •Appetite and satiety regulation
- •Where GLP-1/GIP options are considered
Reported side effects and cautions
- •GI effects similar to other GLP-1 agonists (nausea, etc.)
- •Requires prescription and medical supervision
- •Long-term data still evolving
Dosing protocol described in the literature
- Dosage
- Per prescription (research-phase)
- Frequency
- Weekly
- Administration
- Subcutaneous
- Cycle
- Ongoing per provider
Latest breakthrough; strong human clinical results for weight & metabolic support
Evidence rating: Clinical evidence
Studied in human clinical trials. Some compounds in this tier are approved medicines for specific indications and require a prescription.
Other peptides
Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use Retatrutide (GLP-1/GIP/Glucagon triple agonist). Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.